Evidence map›Paper›PMID 33224139›Full record

ReviewFrontiers in immunology2020

Role of Complement Receptors (CRs) on DCs in Anti-HIV-1 Immunity.

Wilfried Posch, Marta Bermejo-Jambrina, Cornelia Lass-Flörl, Doris Wilflingseder

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Wilfried PoschInstitute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.
Marta Bermejo-JambrinaInstitute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.
Cornelia Lass-FlörlInstitute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.
Doris WilflingsederInstitute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.
Innsbruck Medical University · ATAcademic Medical Center · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Upon entry of human immunodeficiency virus 1 (HIV-1) into the host, innate immune mechanisms are acting as a first line of defense, that considerably also modify adaptive immunity by the provision of specific signals. Innate and adaptive immune responses are intimately linked and dendritic cells (DCs) together with complement (C) play an important role in regulation of adaptive immunity. Initially, the role of complement was considered to primarily support - or COMPLEMENT - cytolytic actions of antibodies or antibody-complexed antigens (immune complexes, ICs) or directly kill the pathogens by complement-mediated lysis. Recently, the role of complement was revised and found to significantly augmenting and modulating adaptive immunity, in particular against viruses. Complement and DCs are therefore predestined to open novel avenues for antiviral research and potential therapeutic interventions. Recent studies on interactions of complement-opsonized HIV-1 with DCs demonstrated a high potential of such primed DCs to initiate efficient antiviral and cytotoxic anti-HIV-1 immunity and complement-coated viral particles shift DCs functions

Indexed as

AnimalsAntigen PresentationAntigens, ViralComplement System ProteinsCytotoxicity, ImmunologicDendritic CellsHIV-1HIV InfectionsHumansImmunityIntegrin alphaXbeta2Macrophage-1 AntigenSignal TransductionVirus InternalizationAntigens, ViralComplement System ProteinsIntegrin alphaXbeta2Macrophage-1 Antigenantigen presentationantiviral immunitycomplement receptorsdendritic cellsHIV-1immune activationSAMHD1type I IFN

Identifiers

PMID33224139
PMCPMC7670068
OpenAlexW3097767248

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.